Analytical challenges and technical limitations in assessing circulating MiRNAs

Thrombosis and Haemostasis

Volumn 108, Issue 4, 2012, Pages 592-598

  Zampetaki, Anna ^a   Mayr, Manuel ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Biomarker; Cardiovascular; Diabetes; MicroRNA

Indexed keywords

LOCKED NUCLEIC ACID; MICRORNA;

CAENORHABDITIS ELEGANS; CELL COMMUNICATION; CENTRIFUGATION; FREEZE THAWING; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ENGINEERING AND GENE TECHNOLOGY; HIGH THROUGHPUT SEQUENCING; HUMAN; LOCKED NUCLEIC ACID MICRORNA ARRAY; MICROFLUIDIC PRIMER EXTENSION ARRAY; NONHUMAN; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE MICROARRAY; PLASMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA EXTRACTION; SENSITIVITY AND SPECIFICITY;

BLOOD CHEMICAL ANALYSIS; DNA PRIMERS; GENE EXPRESSION PROFILING; HUMANS; MICROFLUIDIC ANALYTICAL TECHNIQUES; MICRORNAS; MOLECULAR PROBE TECHNIQUES; NUCLEIC ACID CONFORMATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OLIGONUCLEOTIDES;

EID: 84867278201     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-02-0097     Document Type: Review

References (63)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
2. Lee Y, Ahn C, Han J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003; 425: 415-419.
3. Denli AM, Tops BB, Plasterk RH, et al. Processing of primary microRNAs by the Microprocessor complex. Nature 2004; 432: 231-235.
4. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
5. Guo H, Ingolia NT, Weissman JS, et al. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010; 466: 835-840.
6. Zampetaki A, Mayr M. MicroRNAs in Vascular and Metabolic Disease. Circ Res 2012; 110: 508-522.
7. Zampetaki A, Willeit P, Drozdov I, et al. Profiling of circulating microRNAs: from single biomarkers to re-wired networks. Cardiovasc Res 2012; 93: 555-562.
8. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable bloodbased markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-10518.
9. Zernecke A, Bidzhekov K, Noels H, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009; 2: ra81.
10. Skog J, Wurdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nature Cell Biol 2008; 10: 1470-1476.
11. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, et al. Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci USA 2010; 107: 6328-6333.
12. Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011; 108: 5003-5008.
13. Wang K, Zhang S, Weber J, et al. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res 2010; 38: 7248-7259.
14. Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nature Cell Biol 2011; 13: 423-433.
15. Kirschner MB, Kao SC, Edelman JJ, et al. Haemolysis during sample preparation alters microRNA content of plasma. PloS One 2011; 6: e24145.
16. Duttagupta R, Jiang R, Gollub J, et al. Impact of Cellular miRNAs on Circulating miRNA Biomarker Signatures. PloS One 2011; 6: e20769.
17. McDonald JS, Milosevic D, Reddi HV, et al. Analysis of Circulating MicroRNA: Preanalytical and Analytical Challenges. Clin Chem 2011; 57: 833-840.
18. George JN, Thoi LL, McManus LM, et al. Isolation of human platelet membrane microparticles from plasma and serum. Blood 1982; 60: 834-840.
19. Garcia ME, Blanco JL, Caballero J, et al. Anticoagulants interfere with PCR used to diagnose invasive aspergillosis. J Clin Microbiol 2002; 40: 1567-1568.
20. Willems M, Moshage H, Nevens F, et al. Plasma collected from heparinized blood is not suitable for HCV-RNA detection by conventional RT-PCR assay. J Virol Methods 1993; 42: 127-130.
21. Cui W, Ma J, Wang Y, et al. Plasma miRNA as biomarkers for assessment of totalbody radiation exposure dosimetry. PloS One 2011; 6: e22988.
22. Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. PloS One 2008; 3: e3148.
23. Rio DC, Ares M, Jr., Hannon GJ, et al. Purification of RNA using TRIzol (TRI reagent). Cold Spring Harbor Prot 2010; 2010: pdb prot5439.
24. Zampetaki A, Kiechl S, Drozdov I, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010; 107: 810-817.
25. Fichtlscherer S, De Rosa S, Fox H, et al. Circulating microRNAs in patients with coronary artery disease. Circ Res 2010; 107: 677-684.
26. Andreasen D, Fog JU, Biggs W, et al. Improved microRNA quantification in total RNA from clinical samples. Methods 2010; 50: S6-9.
27. Turchinovich A, Weiz L, Langheinz A, et al. Characterization of extracellular circulating microRNA. Nucleic Acids Res 2011; 39: 7223-7233.
28. Ozsolak F, Milos PM. RNA sequencing: advances, challenges and opportunities. Nature Rev Genet 2011; 12: 87-98.
29. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006.
30. Ach RA, Wang H, Curry B. Measuring microRNAs: comparisons of microarray and quantitative PCR measurements, and of different total RNA prep methods. BMC Biotechnol 2008; 8: 69.
31. Raymond CK, Roberts BS, Garrett-Engele P, et al. Simple, quantitative primer-extension PCR assay for direct monitoring of microRNAs and short-interfering RNAs. RNA 2005; 11: 1737-1744.
32. Pradervand S, Weber J, Lemoine F, et al. Concordance among digital gene expression, microarrays, and qPCR when measuring differential expression of microRNAs. BioTechniques 2010; 48: 219-222.
33. Jensen SG, Lamy P, Rasmussen MH, et al. Evaluation of two commercial global miRNA expression profiling platforms for detection of less abundant miRNAs. BMC Genomics 2011; 12: 435.
34. Ansorge WJ. Next-generation DNA sequencing techniques. New Biotechnol 2009; 25: 195-203.
35. Creighton CJ, Reid JG, Gunaratne PH. Expression profiling of microRNAs by deep sequencing. Briefings Bioinformatics 2009; 10: 490-497.
36. Yin JQ, Zhao RC, Morris KV. Profiling microRNA expression with microarrays. Trends Biotechnol 2008; 26: 70-76.
37. Bargaje R, Hariharan M, Scaria V, et al. Consensus miRNA expression profiles derived from interplatform normalization of microarray data. RNA 2010; 16: 16-25.
38. Shingara J, Keiger K, Shelton J, et al. An optimized isolation and labeling platform for accurate microRNA expression profiling. RNA 2005; 11: 1461-1470.
39. Wang H, Ach RA, Curry B. Direct and sensitive miRNA profiling from low-input total RNA. RNA 2007; 13: 151-159.
40. Chen TS, Lai RC, Lee MM, et al. Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs. Nucleic Acids Res 2010; 38: 215-224.
41. Sah S, McCall MN, Eveleigh D, et al. Performance evaluation of commercial miRNA expression array platforms. BMC Res Notes 2010; 3: 80.
42. Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA 2009; 106: 4402-4407.
43. Castoldi M, Schmidt S, Benes V, et al. A sensitive array for microRNA expression profiling (miChip) based on locked nucleic acids (LNA). RNA 2006; 12: 913-920.
44. Castoldi M, Schmidt S, Benes V, et al. miChip: an array-based method for microRNA expression profiling using locked nucleic acid capture probes. Nature Protocols 2008; 3: 321-329.
45. Li S, Zhu J, Zhang W, et al. Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection. Circulation 2011; 124: 175-184.
46. Chen J, Lozach J, Garcia EW, et al. Highly sensitive and specific microRNA expression profiling using BeadArray technology. Nucleic Acids Res 2008; 36: e87.
47. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838.
48. Jay C, Nemunaitis J, Chen P, et al. miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol 2007; 26: 293-300.
49. Liu CG, Calin GA, Volinia S, et al. MicroRNA expression profiling using microarrays. Nature Protocols 2008; 3: 563-578.
50. Tijsen AJ, Creemers EE, Moerland PD, et al. MiR423-5p as a circulating biomarker for heart failure. Circ Res 2010; 106: 1035-1039.
51. Vorwerk S, Ganter K, Cheng Y, et al. Microfluidic-based enzymatic on-chip labeling of miRNAs. New Biotechnol 2008; 25: 142-149.
52. Chen Y, Gelfond JA, McManus LM, et al. Reproducibility of quantitative RT-PCR array in miRNA expression profiling and comparison with microarray analysis. BMC Genomics 2009; 10: 407.
53. Chen C, Ridzon DA, Broomer AJ, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005; 33: e179.
54. Mestdagh P, Feys T, Bernard N, et al. High-throughput stem-loop RT-qPCR miRNA expression profiling using minute amounts of input RNA. Nucleic Acids Res 2008; 36: e143.
55. Linsen SE, de Wit E, Janssens G, et al. Limitations and possibilities of small RNA digital gene expression profiling. Nature Methods 2009; 6: 474-476.
56. Bryant RJ, Pawlowski T, Catto JW, et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 2012; 106: 768-774.
57. Ballantyne KN, van Oorschot RA, Mitchell RJ. Locked nucleic acids in PCR primers increase sensitivity and performance. Genomics 2008; 91: 301-305.
58. Latorra D, Arar K, Hurley JM. Design considerations and effects of LNA in PCR primers. Mol Cell Probes 2003; 17: 253-259.
59. Levin JD, Fiala D, Samala MF, et al. Position-dependent effects of locked nucleic acid (LNA) on DNA sequencing and PCR primers. Nucleic Acids Res 2006; 34: e142.
60. D'Alessandra Y, Devanna P, Limana F, et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J 2010; 31: 2765-2773.
61. Ji X, Takahashi R, Hiura Y, et al. Plasma miR-208 as a biomarker of myocardial injury. Clin Chem 2009; 55: 1944-1949.
62. Zhang Y, Liu D, Chen X, et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell 2010; 39: 133-144.
63. Zampetaki A, Willeit P, Tilling L, et al. Prospective Study on Circulating MicroRNAs and Risk of Myocardial Infarction. JACC 2012; in press.